Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Increased RHAMM expression relates to ovarian cancer progression.

Buttermore ST, Hoffman MS, Kumar A, Champeaux A, Nicosia SV, Kruk PA.

J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.

2.

Mutational heterogeneity in non-serous ovarian cancers.

Teer JK, Yoder S, Gjyshi A, Nicosia SV, Zhang C, Monteiro ANA.

Sci Rep. 2017 Aug 29;7(1):9728. doi: 10.1038/s41598-017-10432-9.

3.

MicroRNA MiR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22851. No abstract available.

4.

Positive feedback regulation between Akt2 and MyoD during muscle differentiation. CLONING OF Akt2 PROMOTER.

Kaneko S, Feldman RI, Yu L, Wu Z, Gritsko T, Shelley SA, Nicosia SV, Nobori T, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22850. No abstract available.

5.

Inhibition of JNK by cellular stress- and tumor necrosis factor α-induced AKT2 through activation of the NFκB pathway in human epithelial cells.

Yuan ZQ, Feldman RI, Sun M, Olashaw NE, Coppola D, Sussman GE, Shelley SA, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22849. No abstract available.

6.

Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.

Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22848. No abstract available.

7.

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1. IMPLICATION OF AKT2 IN CHEMORESISTANCE.

Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22847. No abstract available.

8.

Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).

Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22846. No abstract available.

9.

ArgBP2γ interacts with Akt and p21-activated kinase-1 and promotes cell survival.

Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22845. No abstract available.

10.

Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway.

Park S, Kim D, Kaneko S, Szewczyk KM, Nicosia SV, Yu H, Jove R, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22844. No abstract available.

11.

Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212.

Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22843. No abstract available.

12.

Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src.

Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22841. No abstract available.

13.

Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.

Lungchukiet P, Sun Y, Kasiappan R, Quarni W, Nicosia SV, Zhang X, Bai W.

J Steroid Biochem Mol Biol. 2015 Apr;148:138-47. doi: 10.1016/j.jsbmb.2014.11.005. Epub 2014 Nov 6. Review.

14.

Urinary interleukin-1β levels among gynecological patients.

Woolery KT, Hoffman MS, Kraft J, Nicosia SV, Kumar A, Kruk PA.

J Ovarian Res. 2014 Nov 18;7:104. doi: 10.1186/s13048-014-0104-4.

15.

HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.

Zhang M, Xiang S, Joo HY, Wang L, Williams KA, Liu W, Hu C, Tong D, Haakenson J, Wang C, Zhang S, Pavlovicz RE, Jones A, Schmidt KH, Tang J, Dong H, Shan B, Fang B, Radhakrishnan R, Glazer PM, Matthias P, Koomen J, Seto E, Bepler G, Nicosia SV, Chen J, Li C, Gu L, Li GM, Bai W, Wang H, Zhang X.

Mol Cell. 2014 Jul 3;55(1):31-46. doi: 10.1016/j.molcel.2014.04.028. Epub 2014 May 29.

16.

Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.

Lee JH, Cragun D, Thompson Z, Coppola D, Nicosia SV, Akbari M, Zhang S, McLaughlin J, Narod S, Schildkraut J, Sellers TA, Pal T.

Genet Test Mol Biomarkers. 2014 Apr;18(4):229-35. doi: 10.1089/gtmb.2013.0393. Epub 2014 Mar 4.

17.

One mouse, one patient paradigm: New avatars of personalized cancer therapy.

Malaney P, Nicosia SV, Davé V.

Cancer Lett. 2014 Mar 1;344(1):1-12. doi: 10.1016/j.canlet.2013.10.010. Epub 2013 Oct 22. Review.

18.

Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration.

Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, Wang C, Bai W, Zhang X.

J Biol Chem. 2013 Nov 15;288(46):33156-70. doi: 10.1074/jbc.M113.472506. Epub 2013 Oct 2.

19.

Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Coppola D, Nicosia SV, Doty A, Sellers TA, Lee JH, Fulp J, Thompson Z, Galeb S, McLaughlin J, Narod SA, Schildkraut J, Pal T.

Anticancer Res. 2012 Nov;32(11):4963-9.

20.

Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

Shan L, Chen YA, Davis L, Han G, Zhu W, Molina AD, Arango H, LaPolla JP, Hoffman MS, Sellers T, Kirby T, Nicosia SV, Sutphen R.

PLoS One. 2012;7(10):e46846. doi: 10.1371/journal.pone.0046846. Epub 2012 Oct 17.

21.

1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498.

Kasiappan R, Shen Z, Tse AK, Jinwal U, Tang J, Lungchukiet P, Sun Y, Kruk P, Nicosia SV, Zhang X, Bai W.

J Biol Chem. 2012 Nov 30;287(49):41297-309. doi: 10.1074/jbc.M112.407189. Epub 2012 Oct 10.

22.

Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.

Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G, Zhang X.

PLoS One. 2012;7(9):e44265. doi: 10.1371/journal.pone.0044265. Epub 2012 Sep 5.

23.

MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2012 Oct 12;287(42):34970-8. doi: 10.1074/jbc.M112.374611. Epub 2012 Aug 27. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22851.

24.

The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.

Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U, Li P, Hann S, Nicosia SV, Wu J, Zhang X, Bai W.

Mol Cell Endocrinol. 2011 May 16;338(1-2):58-67. doi: 10.1016/j.mce.2011.02.023. Epub 2011 Mar 30.

25.

Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.

Yang Y, Tse AK, Li P, Ma Q, Xiang S, Nicosia SV, Seto E, Zhang X, Bai W.

Oncogene. 2011 May 12;30(19):2207-18. doi: 10.1038/onc.2010.600. Epub 2011 Jan 17.

26.

Expression of thyroid transcription factor-1 in malignant pleural effusions.

Khoor A, Byrd-Gloster AL, Nicosia SV.

Pathol Oncol Res. 2011 Jun;17(2):263-7. doi: 10.1007/s12253-010-9308-0. Epub 2010 Sep 17.

PMID:
20848248
27.

Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.

Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV.

Gynecol Oncol. 2010 Apr;117(1):117-24. doi: 10.1016/j.ygyno.2009.12.011. Epub 2010 Jan 13.

PMID:
20071014
28.

Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues.

Drenberg CD, Livingston S, Chen R, Kruk PA, Nicosia SV.

Obstet Gynecol Int. 2009;2009:730739. doi: 10.1155/2009/730739. Epub 2009 Nov 1.

29.

Bing De Ling, a Chinese herbal formula, inhibits cancer cells growth via p53.

Zhang Y, Dong H, Li Z, Xiang S, Zhu Y, Zhang M, Liu J, Bai W, Nicosia SV, Chen J, Zhao RJ, Zhang X.

Front Biosci (Elite Ed). 2010 Jan 1;2:221-30.

PMID:
20036872
30.

Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation.

Anderson NS, Turner L, Livingston S, Chen R, Nicosia SV, Kruk PA.

J Ovarian Res. 2009 Oct 25;2:16. doi: 10.1186/1757-2215-2-16.

31.

Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.

Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ.

Am J Pathol. 2009 Jul;175(1):324-33. doi: 10.2353/ajpath.2009.080767. Epub 2009 Jun 4.

32.

MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation.

Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S, Nawaz Z, Shimojima T, Wang H, Yang Y, Shen Z, Zhang Y, Zhang X, Nicosia SV, Zhang Y, Pledger JW, Chen J, Bai W.

J Biol Chem. 2009 May 22;284(21):13987-4000. doi: 10.1074/jbc.M901758200. Epub 2009 Mar 25.

33.

FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W.

Mol Endocrinol. 2009 Feb;23(2):213-25. doi: 10.1210/me.2008-0147. Epub 2008 Dec 12.

34.

Urinary levels of Bcl-2 are elevated in ovarian cancer patients.

Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA.

Gynecol Oncol. 2009 Jan;112(1):60-7. doi: 10.1016/j.ygyno.2008.09.037. Epub 2008 Nov 12.

35.

Deacetylation of cortactin by SIRT1 promotes cell migration.

Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X.

Oncogene. 2009 Jan 22;28(3):445-60. doi: 10.1038/onc.2008.388. Epub 2008 Oct 13.

PMID:
18850005
36.

P53 enhances ascorbyl stearate-induced G2/M arrest of human ovarian cancer cells.

Naidu KA, Fang Q, Naidu KA, Cheng JQ, Nicosia SV, Coppola D.

Anticancer Res. 2007 Nov-Dec;27(6B):3927-34.

37.

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ.

Cancer Res. 2008 Jan 15;68(2):425-33. doi: 10.1158/0008-5472.CAN-07-2488. Erratum in: Cancer Res. 2008 Mar 1;68(5):1609.

38.

SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress.

Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, Bhalla K, Bai W.

Nat Cell Biol. 2007 Nov;9(11):1253-62. Epub 2007 Oct 14. Erratum in: Nat Cell Biol. 2007 Dec;9(12):1442.

39.

VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent.

Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV, Kruk PA.

Gynecol Oncol. 2007 Sep;106(3):526-37. Epub 2007 Jun 8.

PMID:
17559911
40.

Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS.

Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR.

Brain Res. 2007 Jul 9;1157:126-37. Epub 2007 Apr 24.

PMID:
17512910
41.

Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212.

Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV, Cheng JQ.

J Biol Chem. 2007 Apr 13;282(15):10981-7. Epub 2007 Feb 20. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22843.

42.

Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Lee H, Kim D, Dan HC, Wu EL, Gritsko TM, Cao C, Nicosia SV, Golemis EA, Liu W, Coppola D, Brem SS, Testa JR, Cheng JQ.

Mol Cell Biol. 2007 Mar;27(6):2103-19. Epub 2007 Jan 8.

43.
44.
45.

Vitamin D receptor is a novel drug target for ovarian cancer treatment.

Zhang X, Nicosia SV, Bai W.

Curr Cancer Drug Targets. 2006 May;6(3):229-44. Review.

PMID:
16712459
46.

Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway.

Fang Q, Naidu KA, Naidu KA, Zhao H, Sun M, Dan HC, Nasir A, Kaiser HE, Cheng JQ, Nicosia SV, Coppola D.

Anticancer Res. 2006 Jan-Feb;26(1A):203-9.

47.

The Akt/PKB pathway: molecular target for cancer drug discovery.

Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV.

Oncogene. 2005 Nov 14;24(50):7482-92. Review.

PMID:
16288295
48.

Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway.

Park S, Kim D, Kaneko S, Szewczyk KM, Nicosia SV, Yu H, Jove R, Cheng JQ.

J Biol Chem. 2005 Nov 25;280(47):38932-41. Epub 2005 Sep 20. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22844.

49.

Significance of Fas receptor protein expression in epithelial ovarian cancer.

Reed J, Hakam A, Nicosia SV, Coppola D.

Hum Pathol. 2005 Sep;36(9):971-6.

PMID:
16153459
50.

Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis.

Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W.

J Biol Chem. 2005 Oct 21;280(42):35458-68. Epub 2005 Aug 10.

Supplemental Content

Loading ...
Support Center